NO20090185L - Kontrollerte frigjoringsformuleringer - Google Patents
Kontrollerte frigjoringsformuleringerInfo
- Publication number
- NO20090185L NO20090185L NO20090185A NO20090185A NO20090185L NO 20090185 L NO20090185 L NO 20090185L NO 20090185 A NO20090185 A NO 20090185A NO 20090185 A NO20090185 A NO 20090185A NO 20090185 L NO20090185 L NO 20090185L
- Authority
- NO
- Norway
- Prior art keywords
- core
- release
- formulations
- controlled release
- release formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formuleringer for kontrollert frigjøring som viser en frigjøringsteknikk hovedsakelig i nullte grad, er beskrevet her. Formuleringene omfatter en kjerne omfattende et aktivt middel i kjernen og et vokstilsetningsmiddel som hovedsakelig er belagt med et belegg for forlenget frigjøring. Formuleringen omfatter eventuelt en del for umiddelbar frigjøring, omfattende det aktive middelet for umiddelbar frigjøring i form av for eksempel et belegg plassert på minst en del av kjernen. Feksofenadin/pseudoefedrinkombinasjonsformuleringer, som viser hovedsakelig ingen effekt av mat, er også beskrevet her.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81991406P | 2006-07-11 | 2006-07-11 | |
US85977206P | 2006-11-17 | 2006-11-17 | |
PCT/US2007/015897 WO2008008434A1 (en) | 2006-07-11 | 2007-07-11 | Controlled-release formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090185L true NO20090185L (no) | 2009-03-31 |
Family
ID=38656800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090185A NO20090185L (no) | 2006-07-11 | 2009-01-13 | Kontrollerte frigjoringsformuleringer |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080095843A1 (no) |
EP (1) | EP2046299A1 (no) |
JP (1) | JP2009543780A (no) |
KR (1) | KR20090037930A (no) |
AU (1) | AU2007272951A1 (no) |
CA (1) | CA2658170A1 (no) |
CO (1) | CO6180499A2 (no) |
IL (1) | IL196396A0 (no) |
MX (1) | MX2009000320A (no) |
NO (1) | NO20090185L (no) |
RU (1) | RU2009104001A (no) |
WO (1) | WO2008008434A1 (no) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
ES2653568T3 (es) | 2004-06-12 | 2018-02-07 | Collegium Pharmaceutical, Inc. | Formulaciones de fármacos para la prevención del abuso |
WO2008114280A1 (en) * | 2007-03-21 | 2008-09-25 | Lupin Limited | Novel reduced dose pharmaceutical compositions of fexofenadine and pseudoephedrine |
AU2009226091B2 (en) * | 2008-03-21 | 2014-07-10 | Mylan Pharmaceuticals, Inc. | Extended release formulation containing a wax |
US20100260842A1 (en) * | 2009-04-06 | 2010-10-14 | Rashmi Nair | Pseudoephedrine pharmaceutical formulations |
US20120058185A1 (en) * | 2009-05-22 | 2012-03-08 | Pattanayak Durgaprasad | Stable pharmaceutical compositions of olanzapine and process for their preparation |
US20120064133A1 (en) * | 2009-05-28 | 2012-03-15 | Ishwar Chauhan | Multiparticulate Controlled-Release Selective Serotonin Reuptake Inhibitor Formulations |
JP5641483B2 (ja) | 2009-08-18 | 2014-12-17 | 国立大学法人東北大学 | 持続性ドラッグデリバリーシステム |
US20120141584A1 (en) * | 2009-08-26 | 2012-06-07 | Aptapharma, Inc. | Multilayer Minitablets |
ES2569925T3 (es) | 2009-09-30 | 2016-05-13 | Acura Pharmaceuticals, Inc. | Métodos y composiciones de disuasión del abuso |
WO2011061616A2 (en) * | 2009-11-23 | 2011-05-26 | Micro Labs Limited | Extended release compositions containing tolterodine and process for preparing the same |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
WO2011078993A1 (en) * | 2009-12-21 | 2011-06-30 | Aptapharma, Inc. | Functionally-coated multilayer tablets |
KR101193495B1 (ko) | 2010-02-01 | 2012-10-23 | 한미사이언스 주식회사 | 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물 |
WO2011161504A1 (en) * | 2010-06-23 | 2011-12-29 | Micro Labs Limited | Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof |
LT2826467T (lt) | 2010-12-22 | 2017-09-25 | Purdue Pharma L.P. | Padidinto saugumo kontroliuojamo atpalaidavimo vaisto forma |
EP2654733B1 (en) | 2010-12-23 | 2016-04-06 | Purdue Pharma LP | Tamper resistant solid oral dosage forms |
US9763884B2 (en) * | 2011-05-13 | 2017-09-19 | Eb Ip Hybritabs B.V. | Drug delivery system |
CA2837077A1 (en) * | 2011-06-01 | 2012-12-06 | Fmc Corporation | Controlled release solid dose forms |
JP2013119540A (ja) * | 2011-12-08 | 2013-06-17 | Nipro Corp | 固形医薬組成物およびその製造法 |
JP6176840B2 (ja) * | 2012-06-29 | 2017-08-09 | 高田製薬株式会社 | フェキソフェナジン顆粒製剤及びその製造方法 |
ES2691982T3 (es) | 2012-11-30 | 2018-11-29 | Acura Pharmaceuticals, Inc. | Liberación autorregulada de un principio activo farmacéutico |
AU2014215478B2 (en) | 2013-02-05 | 2018-09-13 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US10596127B2 (en) | 2013-03-14 | 2020-03-24 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
JP2016522188A (ja) * | 2013-05-03 | 2016-07-28 | シンダックス ファーマシューティカルズ,インク. | 癌の処置方法 |
KR101561345B1 (ko) * | 2013-10-17 | 2015-10-16 | 대원제약주식회사 | 제어방출되는 프로피온산 계열의 약제학적 조성물 |
WO2015145461A1 (en) | 2014-03-26 | 2015-10-01 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release biphasic matrix solid dosage form |
WO2017040607A1 (en) | 2015-08-31 | 2017-03-09 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
CN108430465A (zh) * | 2015-09-30 | 2018-08-21 | 韦尔斯利医药有限公司 | 用于缓解尿频的组合物、其制造方法和用途 |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
JP6286096B1 (ja) * | 2017-08-01 | 2018-02-28 | ロート製薬株式会社 | 医薬用錠剤 |
JP2019218313A (ja) | 2018-06-21 | 2019-12-26 | 沢井製薬株式会社 | プソイドエフェドリン又はその薬学的に許容される塩を含有する徐放製剤 |
CN113230235B (zh) * | 2021-04-15 | 2022-11-11 | 海南普利制药股份有限公司 | 含地氯雷他定的复方缓释胶囊及其制备方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5656296A (en) * | 1992-04-29 | 1997-08-12 | Warner-Lambert Company | Dual control sustained release drug delivery systems and methods for preparing same |
DE69527429T2 (de) * | 1994-05-18 | 2003-03-20 | Aventis Pharma Inc | Verfahren zur herstellung von wasserfreien und hydrat-formen von antihistaminischen piperinderivaten, polymerphe und pseudomorphe davon |
US20030045722A1 (en) * | 1994-05-18 | 2003-03-06 | Henton Daniel R. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
EP0811374A1 (en) * | 1996-05-29 | 1997-12-10 | Pfizer Inc. | Combination dosage form comprising cetirizine and pseudoephedrine |
JP4344405B2 (ja) * | 1997-08-26 | 2009-10-14 | アベンティス・ファーマスーティカルズ・インコーポレイテッド | ピペリジノアルカノール−鬱血除去剤の組合せ用医薬組成物 |
AU2277101A (en) * | 1999-12-20 | 2001-07-03 | Schering Corporation | Stable extended release oral dosage composition |
US6613357B2 (en) * | 2000-01-13 | 2003-09-02 | Osmotica Corp. | Osmotic device containing pseudoephedrine and an H1 antagonist |
US7147870B2 (en) * | 2000-01-13 | 2006-12-12 | Osmotica Corp. | Osmotic device containing pseudoephedrine and an H1 antagonist |
WO2001085148A2 (en) * | 2000-05-05 | 2001-11-15 | Aventis Pharmaceuticals Inc. | Packaging regimen of pseudoephedrine hydrochloride and fexofenadine hydrocloride |
US6613906B1 (en) * | 2000-06-06 | 2003-09-02 | Geneva Pharmaceuticals, Inc. | Crystal modification |
CH695216A5 (de) * | 2001-02-23 | 2006-01-31 | Cilag Ag | Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes. |
SK13822003A3 (sk) * | 2001-04-09 | 2004-09-08 | Teva Pharmaceutical Industries Ltd. | Polymorfné formy chloridu fexofenadínu |
US20030021849A1 (en) * | 2001-04-09 | 2003-01-30 | Ben-Zion Dolitzky | Polymorphs of fexofenadine hydrochloride |
US6946146B2 (en) * | 2001-04-18 | 2005-09-20 | Nostrum Pharmaceuticals Inc. | Coating for a sustained release pharmaceutical composition |
US7700779B2 (en) * | 2001-06-18 | 2010-04-20 | Dr. Reddy's Laboratories Limited | Crystalline forms of fexofenadine and its hydrochloride |
DE60225694T2 (de) * | 2001-07-31 | 2008-06-26 | Texcontor Etablissement | Neues polymorph von fexo-fenadin |
US20040044038A1 (en) * | 2002-06-10 | 2004-03-04 | Barnaba Krochmal | Polymorphic form XVI of fexofenadine hydrochloride |
US20070196481A1 (en) * | 2002-07-25 | 2007-08-23 | Amidon Gregory E | Sustained-release tablet composition |
US8216609B2 (en) * | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
US8268352B2 (en) * | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
US20050220877A1 (en) * | 2004-03-31 | 2005-10-06 | Patel Ashish A | Bilayer tablet comprising an antihistamine and a decongestant |
KR20040037045A (ko) * | 2004-04-12 | 2004-05-04 | 최재승 | 경구용 항알레르기 복합제제의 조성물 및 그 제조방법 |
JP2007532687A (ja) * | 2004-04-26 | 2007-11-15 | テバ ファーマシューティカル インダストリーズ リミティド | フェキソフェナジン塩酸塩の結晶形およびその製造方法 |
ITMI20041143A1 (it) * | 2004-06-08 | 2004-09-08 | Dipharma Spa | Polimorfi di fexofenadina e procedimento per la loro preparazione |
ITMI20041568A1 (it) * | 2004-07-30 | 2004-10-30 | Dipharma Spa | "polimorfi di fexofenadina base" |
-
2007
- 2007-07-11 KR KR1020097002597A patent/KR20090037930A/ko not_active Application Discontinuation
- 2007-07-11 MX MX2009000320A patent/MX2009000320A/es not_active Application Discontinuation
- 2007-07-11 EP EP07796824A patent/EP2046299A1/en not_active Withdrawn
- 2007-07-11 CA CA002658170A patent/CA2658170A1/en not_active Abandoned
- 2007-07-11 US US11/827,368 patent/US20080095843A1/en not_active Abandoned
- 2007-07-11 RU RU2009104001/15A patent/RU2009104001A/ru not_active Application Discontinuation
- 2007-07-11 AU AU2007272951A patent/AU2007272951A1/en not_active Abandoned
- 2007-07-11 JP JP2009519527A patent/JP2009543780A/ja active Pending
- 2007-07-11 WO PCT/US2007/015897 patent/WO2008008434A1/en active Application Filing
-
2009
- 2009-01-08 IL IL196396A patent/IL196396A0/en unknown
- 2009-01-13 NO NO20090185A patent/NO20090185L/no not_active Application Discontinuation
- 2009-01-22 CO CO09005062A patent/CO6180499A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2009104001A (ru) | 2010-08-20 |
KR20090037930A (ko) | 2009-04-16 |
US20080095843A1 (en) | 2008-04-24 |
IL196396A0 (en) | 2009-09-22 |
AU2007272951A2 (en) | 2009-03-05 |
AU2007272951A1 (en) | 2008-01-17 |
EP2046299A1 (en) | 2009-04-15 |
CA2658170A1 (en) | 2008-01-17 |
CO6180499A2 (es) | 2010-07-19 |
WO2008008434A1 (en) | 2008-01-17 |
JP2009543780A (ja) | 2009-12-10 |
MX2009000320A (es) | 2009-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20090185L (no) | Kontrollerte frigjoringsformuleringer | |
BRPI0817482B8 (pt) | uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd) | |
ECSP109852A (es) | Uso de homo y copolímeros para la estabilización de formulaciones de principios activos | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
WO2011127070A3 (en) | IRE-1α INHIBITORS | |
NO20081543L (no) | Preparater omfattende darlig vannloselige farmasoytiske midler og antimikroielle midler | |
BRPI0818802A2 (pt) | Artigo absorvente que tem maciez otimizada. | |
BRPI0718688A2 (pt) | Composições de baixa irritação e métodos para preparar as mesmas. | |
BRPI0810390A2 (pt) | Película, composição, e, métodos para administrar um material ativo, para melhorar a estabilidade de uma película e para manter a saúde sistêmica de um mamífero | |
UA99284C2 (ru) | ИНГИБИТОРЫ р70 S6-КИНАЗЫ | |
PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
ATE515260T1 (de) | Stabile nanokapselsysteme für die verabreichung von wirkstoffen | |
BRPI0812136A2 (pt) | aparelhos, sistemas e métodos para determinar o uso complacente d eum aparelho oral. | |
MX2009013332A (es) | Inhibidores de ire-1 alfa. | |
DOP2010000134A (es) | Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos | |
ATE530170T1 (de) | Paliperidonformulierung mit verzögerter freisetzung | |
BRPI0822885A2 (pt) | Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral | |
CL2008001024A1 (es) | Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras | |
AR064201A1 (es) | Agente mateante | |
CO6290686A2 (es) | Dabigatrán para la cateterización cardiaca intervencionista percutánea | |
MX2021004999A (es) | Administracion de butirato, beta-hidroxibutirato, cannabidiol y compuestos relacionaods en seres humanos. | |
NO20080220L (no) | Formuleringer med hoy medikament belastning og doseringsformer | |
DE602007009230D1 (de) | Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting-enzyme inhibitors | |
MX2010008796A (es) | Composiciones formadoras de pelicula para el cuidado personal. | |
NO20080133L (no) | Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |